JPWO2022010813A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022010813A5 JPWO2022010813A5 JP2023501206A JP2023501206A JPWO2022010813A5 JP WO2022010813 A5 JPWO2022010813 A5 JP WO2022010813A5 JP 2023501206 A JP2023501206 A JP 2023501206A JP 2023501206 A JP2023501206 A JP 2023501206A JP WO2022010813 A5 JPWO2022010813 A5 JP WO2022010813A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- polypeptide
- immunogenic composition
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048279P | 2020-07-06 | 2020-07-06 | |
| US63/048,279 | 2020-07-06 | ||
| US202163161136P | 2021-03-15 | 2021-03-15 | |
| US63/161,136 | 2021-03-15 | ||
| PCT/US2021/040392 WO2022010813A2 (en) | 2020-07-06 | 2021-07-03 | Enhancing immune responses through targeted antigen expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536570A JP2023536570A (ja) | 2023-08-28 |
| JPWO2022010813A5 true JPWO2022010813A5 (enExample) | 2024-07-29 |
Family
ID=79553731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501206A Pending JP2023536570A (ja) | 2020-07-06 | 2021-07-03 | 抗原のターゲティング発現による免疫応答の増強法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230241203A1 (enExample) |
| EP (1) | EP4175674A4 (enExample) |
| JP (1) | JP2023536570A (enExample) |
| CN (1) | CN116171168A (enExample) |
| WO (1) | WO2022010813A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114315990B (zh) * | 2022-03-10 | 2022-05-27 | 北京康乐卫士生物技术股份有限公司 | 新型冠状病毒特异性单克隆抗体的制备及其应用 |
| CN114949194B (zh) * | 2022-04-08 | 2023-11-28 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的多肽制剂 |
| WO2025101949A1 (en) * | 2023-11-09 | 2025-05-15 | The Regents Of The University Of California | Engineered phage-based therapeutic compositions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078279A2 (en) * | 2004-04-28 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| AU2005291231B2 (en) * | 2004-10-05 | 2010-12-23 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
| GB201519303D0 (en) * | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
| AU2020357866A1 (en) * | 2019-10-04 | 2022-04-21 | Rutgers, The State University Of New Jersey | Targeted pulmonary delivery compositions and methods using same |
-
2021
- 2021-07-03 WO PCT/US2021/040392 patent/WO2022010813A2/en not_active Ceased
- 2021-07-03 JP JP2023501206A patent/JP2023536570A/ja active Pending
- 2021-07-03 CN CN202180052561.4A patent/CN116171168A/zh active Pending
- 2021-07-03 EP EP21837275.3A patent/EP4175674A4/en active Pending
- 2021-07-03 US US18/004,517 patent/US20230241203A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | mRNA vaccines for COVID-19: what, why and how | |
| JP2020203894A5 (enExample) | ||
| JPWO2021155323A5 (enExample) | ||
| EA007154B1 (ru) | Слитый белок из числа регуляторных/вспомогательных белков вич | |
| JP2004501646A5 (enExample) | ||
| WO2021207848A1 (en) | Mers-cov vaccine | |
| JPWO2019152692A5 (enExample) | ||
| JPWO2021154828A5 (enExample) | ||
| US20220305116A1 (en) | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives | |
| JP2005508158A5 (enExample) | ||
| EP3342866B1 (en) | Polypeptide carrier for presenting target polypeptide and uses thereof | |
| US20230241203A1 (en) | Enhancing immune responses through targeted antigen expression | |
| JPWO2022010813A5 (enExample) | ||
| JP2020522249A5 (enExample) | ||
| JP2007516214A5 (enExample) | ||
| Bae et al. | Molecular identification of diabetogenic viral gene | |
| WO2024094050A1 (en) | Interferon-producing universal sarbecovirus vaccines, and uses thereof | |
| CN115975053A (zh) | 靶向新型冠状病毒的疫苗 | |
| CN117018175A (zh) | 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用 | |
| Lin et al. | Applications of Virus Vector–Mediated Gene Therapy in China | |
| CN113527509B (zh) | 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用 | |
| Balar et al. | Nonreplicating Viral Vectors for Vaccine Delivery | |
| JPWO2021242675A5 (enExample) | ||
| US20240398921A1 (en) | Versatile virus-like-vesicles (vlv) platform for infectious diseases and cancer immunotherapy applications | |
| WO2025180455A1 (en) | A circular rna vaccine against herpes zoster virus and the use thereof |